SynthesisImmunologic research2025
Risk factors for infections in systemic lupus erythematosus: a meta-analysis.
Synthesis in Immunologic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune dysfunction in patients with systemic lupus erythematosus (SLE) increases susceptibility to infections, complicating their management. Identifying risk factors for infections is essential for improving clinical outcomes. A meta-analysis was conducted to evaluate factors associated with infection risk in patients with SLE. Relevant studies were retrieved from PubMed, Web of Science, Embase, and Scopus databases from inception to November 2023. Study quality was assessed using the Newcastle-Ottawa Scale. Meta-analysis was performed using R software (version 4.3.1). Factors analyzed included age, gender, active disease stage, diabetes mellitus, kidney injury, hydroxychloroquine, high-dose glucocorticoids, immunosuppressive drugs, lymphopenia, anti-dsDNA, and complement 3 (C3). Twenty-one studies were included. The analysis identified several factors significantly associated with increased infection risk: age (OR = 1.02, 95% CI 1.01-1.04), being male (OR = 1.66, 95% CI 1.19-2.33), active disease stage (OR = 1.74, 95% CI 1.25-2.43), diabetes mellitus (OR = 1.64, 95% CI 0.92-2.93), kidney injury (OR = 1.78, 95% CI 1.37-2.30), high-dose glucocorticoids (OR = 2.40, 95% CI 1.88-3.80), immunosuppressive drugs (OR = 2.24, 95% CI 1.15-4.38), lymphopenia (OR = 3.59, 95% CI 2.42-5.33), and low C3 (OR = 2.38, 95% CI 1.13-5.03). Older age, male gender, active disease, diabetes, kidney injury, high-dose glucocorticoid use, immunosuppressants, lymphopenia, and decreased C3 levels may increase the risk of infections in SLE. These findings highlight the importance of individualized infection prevention strategies in high-risk patients.
Indexed as
Identifiers
40613863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.